Penserra Capital Management’s Aimmune Therapeutics AIMT Stock Holding History

Penserra Capital Management’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-560	Closed	-$19K	–	1167
2020 Q3	$19K	Buy	+560	New	+$11.9K	﹤0.01%	751

Penserra Capital Management's AIMT Position: Q4 2020 in Review

Penserra Capital Management sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 560 shares — an estimated $19K sold.

Penserra Capital Management first reported a position in AIMT in Q3 2020 and held it in 1 quarter. The position peaked at $19K in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

Penserra Capital Management reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
Penserra Capital Management sold 560 Aimmune Therapeutics shares in Q4 2020, an estimated $19K.
Penserra Capital Management first reported a position in Aimmune Therapeutics in Q3 2020 and held it in 1 quarter.
Penserra Capital Management's Aimmune Therapeutics position peaked at $19K in Q3 2020.
0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Penserra Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.